Cresco Labs (CRLBF) reported $656M in revenue for fiscal 2025, −9.5% year on year. That ranks #2045 by revenue among 2853 SEC filers and #195 in Healthcare. It posted a net loss of −$135M for the same year. Revenue has declined 7.8% a year on average since 2023 ($771M then). The fiscal 2025 balance sheet shows $1.2B in total assets, $57.9M in cash and $417M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $656M | −9.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $325M | −10.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$28.0M | −$135M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$135M | −$61.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $72.9M | −45.0% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $35.1M | +80.3% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | −11.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $340M | −28.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $57.9M | −57.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $417M | −9.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Profile
- Legal name
- Cresco Labs Inc.
- Ticker
- CRLBF
- Exchange
- OTC
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001832928
Filings
- 40-FMar 6, 2026Open filing →
- 40-FMar 14, 2025Open filing →
- 40-FMar 18, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Kiniksa Pharmaceuticals InternationalKNSA | $678M | $59.0M |
| SNDLSNDL | $677M | −$11.3M |
| Ultragenyx PharmaceuticalRARE | $673M | −$575M |
| Cresco LabsCRLBF | $656M | −$135M |
| NovocureNVCR | $655M | −$136M |
| Axsome TherapeuticsAXSM | $638M | −$183M |
| TG TherapeuticsTGTX | $616M | $447M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Cresco Labs — Key figures |url=https://companiesranked.com/en/company/cresco-labs |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Cresco Labs — Key figures. CompaniesRanked. https://companiesranked.com/en/company/cresco-labsBibTeX
@misc{companiesranked-en-company-cresco-labs-2026,
author = {{CompaniesRanked}},
title = {{Cresco Labs — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/cresco-labs}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 40-F · 0001832928-26-000005 · March 6, 2026
{{cite web |title=Cresco Labs — Key figures — 40-F (0001832928-26-000005) |url=https://www.sec.gov/Archives/edgar/data/1832928/000183292826000005/crlbf-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.